AGENHealthcare · BiotechnologyThe 2 Wall Street analysts covering Agenus, Inc. hold a median 12-month price target of $22 — +181.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Agenus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Volatility (20): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Agenus, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on AGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +181.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | B. Riley Securities | Maintains | Buy | $8.00 → $14 |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | $23 → $30 |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 June 2025 | Baird | Maintains | Neutral | — |
| 4 June 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 13 May 2025 | Baird | Maintains | Neutral | — |
| 13 May 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Mar 2025 | Baird | Maintains | Neutral | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 29 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Nov 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 14 Aug 2024 | B. Riley Securities | Maintains | Buy | — |
| 19 July 2024 | Jefferies | Downgrade | Hold | — |
| 18 July 2024 | HC Wainwright & Co. | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 46% of US stocks
Cheaper than 94% of US stocks
Cheaper than 15% of US stocks
Higher than 84% of US stocks
Higher than 74% of US stocks
Higher than 79% of US stocks
Higher than 95% of US stocks
Higher than 96% of US stocks
Higher than 44% of US stocks
Higher than 63% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AGEN appears on the weeks it earns a place.
Zacks Investment Research reported that Agenus (AGEN) lacks the key ingredients for a likely earnings beat in its upcoming report, advising investors to review the key expectations.
Why it matters — AGEN watchers would care because the report suggests the company may face challenges meeting earnings expectations in its next quarterly release.
Agenus announced it will release its second quarter 2026 financial results before market open on August 6, 2026, and will host a webcast later in August to discuss corporate priorities, including progress on the BOT+BAL immunotherapy combination in the Phase 3 ROBBIN trial for neoadjuvant colon cancer.
Why it matters — AGEN watchers will be watching for updates on the company's financial position and clinical progress of its lead immunotherapy combination in the neoadjuvant colon cancer setting.
The 2 Wall Street analysts covering Agenus, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Agenus, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agenus, Inc. 89 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Agenus, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +181.3% from the last close, and Ticker Nerd's factor model ranks Agenus, Inc. 89 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Agenus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.
Agenus, Inc. returned +45.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and the development of therapies designed to activate the immune system against cancer.
The most recent item we track (Zacks Investment Research, 30 July 2026): "Agenus (AGEN) Earnings Expected to Grow: Should You Buy?". Zacks Investment Research reported that Agenus (AGEN) lacks the key ingredients for a likely earnings beat in its upcoming report, advising investors to review the key expectations.
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and the development of therapies designed to activate the immune system against cancer. The company’s current work centers on antibody-based therapeutics, immune checkpoint modulators, cell therapies, vaccines, and vaccine adjuvants, supported by proprietary discovery and manufacturing capabilities. Its pipeline includes programs intended for solid tumors and other difficult-to-treat cancers, with activities spanning research, clinical development, and translational science. Agenus also operates through its subsidiaries and technology platforms to support antibody discovery and cell-therapy development, reflecting a vertically integrated model in biotechnology. Headquartered in Lexington, Massachusetts, and founded in 1994, Agenus serves as a development-stage company within the broader life sciences market, where it contributes to cancer immunotherapy innovation and clinical research.
CEO Dr. Garo H. Armen Ph.D. · 81 employees · United States · https://www.agenusbio.com